Literature DB >> 6148657

Captopril administration in pregnancy impairs fetal angiotensin converting enzyme activity and neonatal adaptation.

M J Boutroy, P Vert, B Hurault de Ligny, A Miton.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6148657     DOI: 10.1016/s0140-6736(84)90695-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  10 in total

Review 1.  The treatment of hypertension in pregnancy. Clinical pharmacokinetic considerations.

Authors:  C Knott
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

2.  Successful pregnancy with scleroderma renal disease and pulmonary hypertension in a patient using angiotensin converting enzyme inhibitors.

Authors:  B A Baethge; R E Wolf
Journal:  Ann Rheum Dis       Date:  1989-09       Impact factor: 19.103

Review 3.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

Review 4.  Adverse reactions with angiotensin converting enzyme (ACE) inhibitors.

Authors:  R DiBianco
Journal:  Med Toxicol       Date:  1986 Mar-Apr

Review 5.  Adverse effects of angiotensin converting enzyme (ACE) inhibitors. An update.

Authors:  R C Parish; L J Miller
Journal:  Drug Saf       Date:  1992 Jan-Feb       Impact factor: 5.606

6.  Idiopathic dilated cardiomyopathy in pregnancy.

Authors:  M Mazor; E Levitas; Y Gussarsky; S Friedman; J R Leiberman
Journal:  Arch Gynecol Obstet       Date:  1994       Impact factor: 2.344

7.  Effects of captopril on the human foetal placental circulation: an interaction with bradykinin and angiotensin I.

Authors:  R de Moura; M A Lopes
Journal:  Br J Clin Pharmacol       Date:  1995-05       Impact factor: 4.335

Review 8.  Pharmacokinetic optimisation of angiotensin converting enzyme (ACE) inhibitor therapy.

Authors:  M Burnier; J Biollaz
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 9.  Clinical pharmacokinetics of vasodilators. Part II.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

Review 10.  Recognition and management of angiotensin converting enzyme inhibitor fetopathy.

Authors:  A B Sedman; D B Kershaw; T E Bunchman
Journal:  Pediatr Nephrol       Date:  1995-06       Impact factor: 3.714

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.